AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Trial: 3730230
Drug: Alcuronium 0.3
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Alcuronium 0.3 mg kg‐1 with increased priming portion
Trial: 25008027
Drug: Prasugrel 5-mg
RxNorm normalized name: prasugrel 5 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 5-mg
Trial: 25008027
Drug: Prasugrel 10-mg
RxNorm normalized name: prasugrel 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Prasugrel 10-mg
Trial: 25008027
Drug: Clopidogrel 75-mg
RxNorm normalized name: clopidogrel 75 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Clopidogrel 75-mg
Trial: 23433324
Drug: 500 mg
RxNorm normalized name: bran 500 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 500 mg of intramuscular 17P, repeated twice weekly until 36 weeks or preterm delivery
Trial: 20101185
Drug: Risperidone long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone long-acting therapy (RLAT) 25 or 50 mg every 2 weeks
Trial: 21999370
Drug: Risperidone long-acting
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Risperidone long-acting therapy (RLAT)
Trial: 18439282
Drug: Ultrasound physical
RxNorm normalized name: hypochlorite
DrugBank: Hypochlorite (DB11123)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ultrasound physical therapy (UPT)
Trial: 12672938
Drug: Combined supplementation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combined supplementation with 91 mg (136 iu) α-tocopherol and 250 mg of slow-release vitamin C twice a day for 3 years
Trial: 1908372
Drug: Cimetidine 200
RxNorm normalized name: cimetidine 200 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Cimetidine 200 mg q.i.d. for 4 weeks
Trial: 6857507
Drug: Low‐dose subcutaneous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low‐dose subcutaneous heparin
Trial: 6857507
Drug: Intermittent sequential
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intermittent sequential compression and thromboembolism‐deterrent (TED) stockings
Trial: 25583271
Drug: Modular treatment
RxNorm normalized name: Hongo Killer Treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Modular treatment
Trial: 25583271
Drug: Standard manualized
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard manualized treatment
Trial: 24507754
Drug: Warming blood
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Warming blood transfusion and infusion (WBI)
Trial: 12065142
Drug: Active management
RxNorm normalized name: Activated Charcoal
DrugBank: Activated charcoal (DB09278)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Active management of the third stage of labor with uterotonic drugs (Oxytocin preferred)
Trial: 8539677
Drug: CPAP titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP titration using full polysomnography
Trial: 8539677
Drug: CPAP titration
FDA approved: no
EMA approved: no
PMDA approved: no
Description: CPAP titration using night time respiratory recordings
Trial: 2482193
Drug: Anthracyclines 0.2
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Anthracyclines 0.2 mumol/l
Trial: 2482193
Drug: Ara-C 0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ara-C 0.5 mumol/l
Trial: 2482193
Drug: Combination of
RxNorm normalized name: combination of rauwolfia alkaloids and diuretics incl. other combinations
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Combination of anthracyclines and Ara-C
Trial: 2482193
Drug: Incubations with
RxNorm normalized name: Primatene with ephedrine Pill
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Incubations with 0.2 mumol/l anthracyclines and 0.5 mumol/l Ara-C
Trial: 2482193
Drug: In vitro
RxNorm normalized name: glucuronidase in vitro test
FDA approved: no
EMA approved: no
PMDA approved: no
Description: In vitro drug sensitivity
Trial: 27932540
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group received treatment after three months
Trial: 23670112
Drug: Two-session intervention
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Two-session intervention aimed at increasing adherence via implementation intentions and modifying mistaken beliefs about medication/stroke.
Trial: 19552805
Drug: Corticosteroid injection
RxNorm normalized name: CORTICOSTEROIDS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Corticosteroid injection with physiotherapy (8 sessions over 8 weeks)
Trial: 19552805
Drug: Saline injection
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline injection with physiotherapy (8 sessions over 8 weeks)
Trial: 11943519
Drug: Bupivacaine 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 180 mg with midazolam 20 mg (HM group)
Trial: 11943519
Drug: Bupivacaine 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 90 mg with midazolam 20 mg (LM group)
Trial: 11943519
Drug: Bupivacaine 180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 180 mg without midazolam (HC group)
Trial: 11943519
Drug: Bupivacaine 90
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Bupivacaine 90 mg without midazolam (LC group)
Trial: 9495418
Drug: Epidural infusion
RxNorm normalized name: epidural administration set EPIDURAL INFUSION SETS-PARAPHERNALIA
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Epidural infusion of alfentanil (0.36 mg/h) plus bupivacaine (10 mg/h)
Trial: 9495418
Drug: i.v. infusion
FDA approved: no
EMA approved: no
PMDA approved: no
Description: i.v. infusion of alfentanil (0.36 mg/h) plus bupivacaine (10 mg/h)
Trial: 7710445
Drug: Ranitidine 150
RxNorm normalized name: ranitidine 150 MG
DrugBank: Ranitidine (DB00863)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Ranitidine 150 mg b.i.d. and clarithromycin 500 mg q.i.d. (group 1)
Trial: 7710445
Drug: Ranitidine 300
RxNorm normalized name: ranitidine 300 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ranitidine 300 mg q.i.d. and clarithromycin 500 mg q.i.d. (group 2)
Trial: 30886131
Drug: Transversalis fascia
RxNorm normalized name: OCTINOXATE .012 mL in 6 mL / OCTISALATE .12 mL in 6 mL TOPICAL CREAM [RIMMEL LONDON MOISTURE RENEW LIPGLOSS - FUSCIA THERAPHY (345)]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transversalis fascia plane (TFP) block with 20 ml of 0.5% ropivacaine
Trial: 28796053
Drug: 14-day berberine-containing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 14-day berberine-containing quadruple therapy
Trial: 23174856
Drug: Nitrate-rich concentrated
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate-rich concentrated beetroot juice (BR; 2 × 70 ml/day, ∼9.6 mmol/day NO(3)(‐))
Trial: 23174856
Drug: Nitrate-depleted beetroot
RxNorm normalized name: Nitrate
DrugBank: Nitrate (DB14049)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Nitrate-depleted beetroot juice placebo (PL; 2 × 70 ml/day, ∼0.01 mmol/day NO(3)(‐))
Trial: 21774637
Drug: Preparation without
RxNorm normalized name: cranberry preparation
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Preparation without teaching
Trial: 21774637
Drug: Teaching vs
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teaching vs Preparation
Trial: 21774637
Drug: Teaching vs
RxNorm normalized name: By Ache
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Teaching vs Preparation (60 days later)
Trial: 15753134
Drug: High-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat meal (17.5 g fat)
Trial: 15753134
Drug: Low-fat meal
RxNorm normalized name: bone meal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low-fat meal (2.7 g fat)
Trial: 15753134
Drug: High-fat toast
RxNorm normalized name: Hard fat
DrugBank: Hard fat (DB11578)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: High-fat toast and butter (17.5 g fat)
Trial: 15753134
Drug: Vitamin E
RxNorm normalized name: Vitamin E
DrugBank: Vitamin E (DB00163)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vitamin E supplementation (400 mg/day, 4 weeks)
Trial: 7742830
Drug: Oral theophylline
RxNorm normalized name: theophylline Oral Capsule
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral theophylline (350 mg b.i.d.)
Trial: 2330167
Drug: Vacu‐Cut needle
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Vacu‐Cut needle (19.5 G)
Trial: 2330167
Drug: Menghini needle
RxNorm normalized name: NEEDLE
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Menghini needle (17 G)
Trial: 7016124
Drug: Praziquantel (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Praziquantel (1 x 30 mg/kg, 1 x 40 mg/kg, 2 x 20 mg/kg)
Trial: 7016124
Drug: Placebo (1
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo (1 x 40 mg/kg)
Trial: 15385359
Drug: Isoflurane inhalation
RxNorm normalized name: isoflurane INHALATION GAS
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Isoflurane inhalation combined with positive pressure ventilation (PPV)
Trial: 11496849
Drug: Antiarrhythmic-drug therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Antiarrhythmic-drug therapy
Trial: 7913326
Drug: Zidovudine 500
RxNorm normalized name: Zidovudine
DrugBank: Zidovudine (DB00495)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Zidovudine 500 mg twice daily for 104 weeks (initially 250 mg four times daily for the first 4 weeks)
Trial: 7913326
Drug: Placebo twice
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Placebo twice daily for 104 weeks
Trial: 30169323
Drug: Late parenteral
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Late parenteral nutrition (withholding for 1 week)
Trial: 30169323
Drug: Early parenteral
RxNorm normalized name: benzyl alcohol
DrugBank: Benzyl alcohol (DB06770)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Early parenteral nutrition (initiated within 24 h)
Trial: 22928590
Drug: BIS biosignal
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS biosignal with 0.6 mg/kg rocuronium
Trial: 22928590
Drug: BIS biosignal
RxNorm normalized name: bis-ethoxydiglycol succinate
FDA approved: no
EMA approved: no
PMDA approved: no
Description: BIS biosignal with 1.2 mg/kg rocuronium
Trial: 22928590
Drug: Entropy biosignal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entropy biosignal with 0.6 mg/kg rocuronium
Trial: 22928590
Drug: Entropy biosignal
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Entropy biosignal with 1.2 mg/kg rocuronium
Trial: 21115455
Drug: Vancomycin plus
RxNorm normalized name: Vancomycin
DrugBank: Vancomycin (DB00512)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Vancomycin plus aztreonam 1 g every 12 h for 5-14 days
Trial: 17976094
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium (4 grams)
Trial: 17976094
Drug: Intravenous ibutilide
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous ibutilide without magnesium
Trial: 17976094
Drug: Intravenous magnesium
RxNorm normalized name: immunoglobulins, intravenous
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intravenous magnesium (1 to 3 grams)
Trial: 17976094
Drug: No adjunctive
FDA approved: no
EMA approved: no
PMDA approved: no
Description: No adjunctive magnesium
Trial: 8186350
Drug: Pantoprazole 40
RxNorm normalized name: pantoprazole 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Pantoprazole 40 mg at breakfast
Trial: 3285638
Drug: 0.6 mg/kg
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.6 mg/kg dexamethasone
Trial: 24026991
Drug: Low level
RxNorm normalized name: low-density polyethylene
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Low level laser therapy (LLLT) with wavelength of 78 nm and 2.5 j/cm2, two times a week for 5 min, for one month
Trial: 19359232
Drug: Intrathecal therapy
RxNorm normalized name: Monistat Simple Therapy
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Intrathecal therapy with 1 500 IU of antitetanus serum and 1.5 g of intravenous metronidazole daily
Trial: 19359232
Drug: Standard treatment
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Standard treatment of 9 000 IU of antitetanus serum (4 500 IU cutaneously and 4 500 IU intramuscularly)
Trial: 16176204
Drug: Repaglinide (2-9
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide (2-9 mg/day, average 5.9 mg)
Trial: 16176204
Drug: Repaglinide (0.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Repaglinide (0.5 mg acute exposure)
Trial: 1354276
Drug: Ribose 60
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ribose 60 g daily in four doses by mouth for 3 days
Trial: 30280657
Drug: Brigatinib (180
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Brigatinib (180 mg once daily with a 7-day lead-in period at 90 mg)
Trial: 25188501
Drug: AOM 400
RxNorm normalized name: ethanol
DrugBank: Ethanol (DB00898)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: AOM 400 mg
Trial: 22640674
Drug: Mini-implant system
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Mini-implant system
Trial: 17957155
Drug: Probiotic formula
RxNorm normalized name: Probiotic Formula
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Probiotic formula (LGG and Bifidobacterium longum) administered during the first 6 months of life
Trial: 17957155
Drug: Control group
RxNorm normalized name: meningococcal group B vaccine Prefilled Syringe [Trumenba]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Control group (no probiotic administration)
Trial: 15586515
Drug: 0.25% bupivicaine
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 0.25% bupivicaine via elastomeric infusion pump (ON-Q) for 48 hours at 2 cc/h
Trial: 15586515
Drug: Saline solution
RxNorm normalized name: Unisol 4 Saline Solution
DrugBank: Sodium chloride (DB09153)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Saline solution via elastomeric infusion pump (ON-Q) for 48 hours at 2 cc/h
Trial: 3340474
Drug: Simultaneous administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Simultaneous administration of MMR, DTP, and OPV vaccines
Trial: 3340474
Drug: Sequential administration
RxNorm normalized name: polidocanol
DrugBank: Polidocanol (DB06811)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Sequential administration of MMR followed by booster doses of DTP and OPV 2 months later
Trial: 28599629
Drug: Methoxamine 4
RxNorm normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methoxamine 4 μg·kg‐1·min‐1 (M3)
Trial: 28599629
Drug: Methoxamine 2
RxNorm normalized name: methoxamine 20 MG/ML
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Methoxamine 2 μg·kg‐1·min‐1 (M1)
Trial: 28599629
Drug: Methoxamine 3
RxNorm normalized name: methoxamine
DrugBank: Methoxamine (DB00723)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Methoxamine 3 μg·kg‐1·min‐1 (M2)
Trial: 24589564
Drug: Subcutaneous abdominal
RxNorm normalized name: PAD,ABDOMINAL
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Subcutaneous abdominal adipose tissue (SAT)
Trial: 19536915
Drug: Additional 12-week
RxNorm normalized name: risedronate
DrugBank: Risedronic acid (DB00884)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Additional 12-week treatment with varenicline
Trial: 15273395
Drug: Synthetic conjugate
RxNorm normalized name: synthetic conjugated estrogens, A
DrugBank: Synthetic Conjugated Estrogens, A (DB09317)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Synthetic conjugate polysaccharide vaccine against Hib
Trial: 10223783
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg BMS‐186716
Trial: 7872185
Drug: Enoxaparin (combined
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Enoxaparin (combined 40 mg and 60 mg)
Trial: 359019
Drug: Tienylic acid
RxNorm normalized name: 3-(3-methyl-2-thienyl)acrylic acid
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tienylic acid (500 mg)
Trial: 25751116
Drug: Community Treatment
RxNorm normalized name: ALCOHOL 80 mL in 100 mL TOPICAL LIQUID [Sanitizing Liquid for Community Support]
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Community Treatment by Experts
Trial: 30948365
Drug: Sequential high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential high-dose chemotherapy (sHD) - 2 weekly 3-day blocks with cytarabine 2 g/m2 twice a day for 2 days plus idarubicin
Trial: 30948365
Drug: Standard-intensity idarubicin-cytarabine-etoposide
RxNorm normalized name: Etoposide
DrugBank: Etoposide (DB00773)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Standard-intensity idarubicin-cytarabine-etoposide (ICE) chemotherapy
Trial: 30948365
Drug: Sequential high-dose
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Sequential high-dose chemotherapy (sHD)
Trial: 28166521
Drug: Tolvaptan (daily
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tolvaptan (daily split doses titrated to tolerance: 30/15, 45/15, 60/30, or 90/30 mg) for 12 months
Trial: 21781648
Drug: Ibuprofen (800
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Ibuprofen (800 mg taken orally thrice daily)
Trial: 21781648
Drug: Oral Diclofenac
RxNorm normalized name: diclofenac Oral Solution
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Oral Diclofenac (75 mg taken orally twice daily)
Trial: 21781648
Drug: Diclofenac Epolamine
RxNorm normalized name: Diclofenac Epolamine
DrugBank: Diclofenac (DB00586)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Diclofenac Epolamine Topical Patch (DETP, 1.3% applied topically twice daily)
Trial: 21781648
Drug: Furosemide (20
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Furosemide (20 mg/2 min intravenously)
Trial: 19041216
Drug: Midazolam (increasing
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Midazolam (increasing doses)
Trial: 14646402
Drug: Tibolone (2.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Tibolone (2.5 mg once a day)
Trial: 11605698
Drug: Colesevelam hydrochloride
RxNorm normalized name: Colesevelam Hydrochloride
DrugBank: Colesevelam (DB00930)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Colesevelam hydrochloride (2.3 g/d, 3.0 g/d, 3.8 g/d, or 4.5 g/d)
Trial: 7916039
Drug: Dacarbazine (DTIC)
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine (DTIC) at 3,900 mg/m2 with cyclophosphamide (7.2 g/m2), carmustine (600 mg/m2), etoposide (2.4 g/m2)
Trial: 7916039
Drug: Dacarbazine (DTIC)
RxNorm normalized name: Dacarbazine
DrugBank: Dacarbazine (DB00851)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Dacarbazine (DTIC) at 3,900 mg/m2 with CBV regimen
Trial: 1590872
Drug: Prostaglandin E2
RxNorm normalized name: Prostaglandin E2
DrugBank: Dinoprostone (DB00917)
FDA approved: yes
EMA approved: no
PMDA approved: yes
Description: Prostaglandin E2 gel (1 mg intracervically)
Trial: 27451978
Drug: Asparaginase (ASP)
RxNorm normalized name: Asparaginase
DrugBank: Asparaginase Erwinia chrysanthemi (DB08886)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Asparaginase (ASP) treatment
Trial: 27451978
Drug: Permanent insulin
RxNorm normalized name: INSULIN
DrugBank: Insulin beef (DB09456)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Permanent insulin therapy
Trial: 25527735
Drug: Green tea
RxNorm normalized name: Green Tea
DrugBank: Green tea leaf (DB14307)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Green tea (2 × 150 ml of 1% w/v tea/day)
Trial: 16688105
Drug: Scaling and
RxNorm normalized name: cytarabine and daunorubicin
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Scaling and root planing with Odontoson M irrigated with a 10% iodised solution
Trial: 10390663
Drug: Droperidol (5-7.5
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Droperidol (5-7.5 mg)
Trial: 9014793
Drug: Transdermal glyceryl
RxNorm normalized name: glyceryl
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Transdermal glyceryl trinitrate (10 mg per day)
Trial: 1569240
Drug: 90 mg
RxNorm normalized name: papain 90 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 90 mg ketorolac
Trial: 1569240
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg meperidine
Trial: 1569240
Drug: ketorolac (30
FDA approved: no
EMA approved: no
PMDA approved: no
Description: ketorolac (30 mg or 90 mg)
Trial: 6488765
Drug: 7 proprietary
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 7 proprietary corticosteroid creams
Trial: 19352055
Drug: Multi-daily insulin
RxNorm normalized name: Parasedge Multi
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Multi-daily insulin injections therapy (MDI)
Trial: 16144857
Drug: Heparin (HDhep)
DrugBank: Heparin (DB01109)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Heparin (HDhep)
Trial: 10632654
Drug: 40 mg
RxNorm normalized name: rutin 40 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 40 mg extended-release cisapride
Trial: 10632654
Drug: 10 mg
RxNorm normalized name: biotin 10 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 10 mg immediate-release cisapride
Trial: 8819499
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg of codeine plus placebo
Trial: 8819499
Drug: 120 mg
RxNorm normalized name: papain 120 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 120 mg of codeine plus 100 mg of quinidine
Trial: 8819499
Drug: 100 mg
RxNorm normalized name: urea 100 MG
FDA approved: no
EMA approved: no
PMDA approved: no
Description: 100 mg of quinidine plus placebo
Trial: 1576068
Drug: Buffered aspirin
RxNorm normalized name: Buffered Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buffered aspirin 500 mg
Trial: 1576068
Drug: Buffered aspirin
RxNorm normalized name: Buffered Aspirin
DrugBank: Acetylsalicylic acid (DB00945)
FDA approved: yes
EMA approved: no
PMDA approved: no
Description: Buffered aspirin preparations
Trial: 1576068
Drug: Aspirin esterase
RxNorm normalized name: cocaine esterase
DrugBank: COCAINE ESTERASE (RBP-8000) (DB19225)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Aspirin esterase activity
Trial: 2864935
Drug: Etilefrine pivalate
RxNorm normalized name: etilefrine
DrugBank: Etilefrine (DB08985)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Etilefrine pivalate (20 mg, oral administration once daily for 2-6 months)
Trial: 26325116
Drug: Psyllium fiber
RxNorm normalized name: Konsyl Daily Psyllium Fiber
DrugBank: Plantago seed (DB11097)
FDA approved: no
EMA approved: no
PMDA approved: no
Description: Psyllium fiber (3.5 g/day)